{
    "clinical_study": {
        "@rank": "116013", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Arm", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy\n      subjects and subjects with mild atopic asthma."
        }, 
        "brief_title": "A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "A single SC or IV dose administration of AMG 282 to healthy subjects and subjects with mild\n      atopic asthma will exhibit an acceptable safety and tolerability profile within the dose\n      ranges studied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (All subjects)\n\n          -  Is a current non-smoker, has not used any nicotine or tobacco containing products\n             (including but not limited to:  snuff, chewing tobacco, cigars, cigarettes, pipes, or\n             nicotine patches) within the last 6 months, and cumulative smoking history is \u226410\n             pack years.\n\n          -  Females must be of documented non-reproductive potential (ie, postmenopausal [see\n             definition below]; OR history of hysterectomy; OR history of bilateral salpingectomy;\n             OR history of bilateral oophorectomy).\n\n          -  Body mass index (BMI) between \u2265 18.0 and \u2264 32.0 kg/m2 at screening. (Subjects with\n             mild atopic asthma only)\n\n          -  Documented history of mild, stable atopic asthma within 2 years of screening.\n\n          -  Has used only inhaled short-acting \u03b22-agonists (less than twice weekly) to treat\n             asthma.\n\n          -  Pre-bronchodilator forced expiratory volume in 1 second (FEV1) > 70% predicted at\n             screening.\n\n        Exclusion Criteria\n\n        (All subjects)\n\n          -  History or evidence of a clinically significant disorder, condition or disease that,\n             in the opinion of the Principal Investigator or Amgen medical monitor would pose a\n             risk to subject safety or interfere with the study evaluation, procedures, or\n             completion.\n\n          -  Subject has a history of residential exposure to tuberculosis without a documented\n             history of prophylactic treatment of tuberculosis or subject has a positive purified\n             protein derivative (PPD) or QuantiFERON test at screening. Subjects with a documented\n             negative PPD or QuantiFERON test within 4 weeks prior to screening who have no known\n             tuberculosis exposure and have not traveled to an area with tuberculosis do not need\n             to have a test performed at screening.\n\n          -  Has donated or lost \u2265 500 mL of blood or plasma within 8 weeks of administration of\n             the first dose of IP.\n\n        Other criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928368", 
            "org_study_id": "20110235"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Single dose either subcutaneously or intravenously  on day 1.", 
                "intervention_name": "AMG 282", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "description": "Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.", 
                "intervention_name": "AMG 282 Matching Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Mild asthma", 
            "Atopic asthma", 
            "Healthy volunteers", 
            "First-in-human"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Costa Mesa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92626"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma", 
        "other_outcome": {
            "measure": "Measurement of various pharmacodynamic biomarkers in subjects with mild atopic asthma", 
            "safety_issue": "No", 
            "time_frame": "Up to day 141"
        }, 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of treatment emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 141"
            }, 
            {
                "measure": "Incidence of abnormal clinically significant vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 141"
            }, 
            {
                "measure": "Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 141"
            }, 
            {
                "measure": "Incidence of abnormal clinically significant ECG results", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 141"
            }, 
            {
                "measure": "Incidence of anti-AMG 282 antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928368"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Determination of various PK parameters including tmax, AUClast and Cmax", 
            "safety_issue": "No", 
            "time_frame": "Up to day 141"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}